Introducing a new scientific initiative for clinicians in AML from MD Education.
Every month one of the chairs, Dr. Naval Daver or Prof. Charlie Craddock, will interview a leading clinical expert in the area of AML. They will dive deep into hot topics and have open debate on current issues within the AML field. Each expert presentation is followed by a question and answer session with the chair, and includes downloadable slides to enhance understanding.
- 24 leading specialists in AML
- 24 educational discussions online
- 20-minute presentations with slides followed by a 10-minute Q&A session with one chair and two guest speakers every month
Co-chair
Naval Daver, MD
University of Texas MD Anderson Cancer Center, USA
Co-chair
Charlie Craddock, MD
Queen Elizabeth Hospital, Birmingham, U.K.
Chair: Naval Daver
October 2023
Role of MRD in transplant decision making in AML
Roland Walter
University of Washington, USA
Updates and future directions for post-transplant maintenance
Charlie Craddock
Queen Elizabeth Hospital, UK
Chair: Charlie Craddock
November 2023
Who should we transplant in AML and how: moving towards greater precision in transplant decision making
Alessandro Rambaldi
University of Milan, IT
CPX351 in Frontline AML: Current status and Future directions: Real world CPX analysis
Christina Rautenburg
University Hospital Essen, DE
Chair: Charlie Craddock
December 2023
Novel strategies with the potential to improve outcomes in patients treated with HMA-venetoclax: up-front triplets versus sequential add-on approaches
Naval Daver
MD Anderson Cancer Center, USA
Updates on current status of Menin inhibitor single agent: Efficacy, safety, biomarkers of response and mechanisms of resistance
Ghayas Issa
MD Anderson Cancer Center, USA
Chair: Naval Daver
January/2024
Role of MRD in transplant decision making in AML
Roland Walter
University of Washington, USA
Updates and future directions for post-transplant maintenance
Charlie Craddock
Queen Elizabeth Hospital, UK
Chair: Charlie Craddock
February/2024
Who should we transplant in AML and how: moving towards greater precision in transplant decision making
Alessandro Rambaldi
University of Milan, IT
CPX351 in Frontline AML: Current status and Future directions: Real world CPX analysis
Christina Rautenburg
University Hospital Essen, DE
Chair: Charlie Craddock
March/2024
Novel strategies with the potential to improve outcomes in patients treated with HMA-venetoclax: up-front triplets versus sequential add-on approaches
Naval Daver
MD Anderson Cancer Center, USA
Updates on current status of Menin inhibitor single agent: Efficacy, safety, biomarkers of response and mechanisms of resistance
Ghayas Issa
MD Anderson Cancer Center, USA
Chair: Naval Daver
April/2024
Novel immunotherapeutic approaches in AML: Bispecific Antibodies: MOA and clinical development
Marion Subklewe
Gene Center, USA
Novel immunotherapeutic approaches in AML: CART therapies in AML: current status and future prospects
Saar Gill
University of Pennsylvania, USA
Chair: Charlie Craddock
May/2024
TP53 targeted therapies in AML: Current status and emerging therapies
Paresh Vyas
University of Oxford, UK
IDH-1 and IDH-2 inhibitors: Targeted therapies for unfit patience in AML moving from R/R to Frontline use
Courtney Di Nardo
MD Anderson Cancer Center, USA
Chair: Naval Daver
June/2024
Optimizing outcomes in older adults treated with venetoclax based therapies Mechanisms of resistance and potential combinations
Andrew Wei
Monash University, AU
Updates on ELN2022 and integrating genomic information into decision making in AML
Hartmut Doehner
University Hospital of Ulm, DE
Chair: Charlie Craddock
July/2024
Innovative treatment strategies in fit and unfit adults with Flt3+ AML
Jessica Altman
University of Pennsylvania, USA
NPM1 directed therapies: Optimal application in frontline or MRD+ setting
Richard Dillon
King’s College London, UK
Chair: Naval Daver
August/2024
Novel relapse strategies in relapsed AML
Christoph Rollig
University Hospital Carl Gustav Carus, DE
Familial AML
George Vassiliou
University of Cambridge, UK
Chair: Charlie Craddock
September/2024
Antibody based therapies in AML- Mylotarg and beyond
Amir Fathi
Dana-Farber /Harvard Cancer Center, USA
Improving outcomes in adults with APML
Steve Knapper
Cardiff University, UK
Chair: Naval Daver
October/2024
Molecular prognostication and genomics of newly diagnosed AML
Marina Konopleva
Montefiore Einstein Cancer Center, USA
Role of MRD in optimizing outcomes in older adults treated with HMA/VEN regimens-is it ever possible to safely stop therapy
Daniel Pollyea
University of Colorado, USA
Chair: Charlie Craddock
November/2024
Integrating MRD into management of fit adults with AML: who, when and how?
Sylvie Freeman
University of Birmingham, UK
The role of venetoclax in improving outcomes in fit adults with newly diagnosed and relapsed AML
Farhad Ravandi
MD Anderson Cancer Center, USA
Chair: Naval Daver
December/2024
Maintenance based approaches and future of maintenance therapy in AML approaches to maintenance in AML
GaiI Roboz
Weill Medical College of Cornell University, USA
Immune based therapies in AML and MDS: Future directions and prospects
Amer Zeidan
Yale University, UK
